⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

March 14, 2024Science

‘Damning’ FDA inspection report undermines Alzheimer’s drug

View Full Paper

Ask AI

Bookmark

Share

Abstract

Inspectors faulted analyses of clinical trial samples by Hoau-Yan Wang for drug developer Cassava Sciences

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Charles Piller (2024) studied this question.

synapsesocial.com/papers/68e7410eb6db6435876ba615 https://doi.org/10.1126/science.adp1964

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1FDA position statement “Early Alzheimer's disease: Developing drugs for treatment, Guidance for Industry”Clinical Guideline · 2018 · 81 citations
2Med Check: Aduhelm, Deep Brain Stimulation System, Narcan and More2024
3MedCheck: Psilocybin for Depression, LSD for Anxiety, Donanemab, LSD, and More2024
4Challenges in Alzheimer’s Drug Development: Failures, Therapeutic Barriers and Clinical TranslationHuman Clinical Trial · 2026
5New Alzheimer’s drug clears FDA advisory vote despite unknowns2024 · 3 citations